

Pharmacy Prior Approval Request for Movement Disorders: Ingrezza

Beneficiary Information

1. Beneficiary Last Nam	e:2. First Name:	
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Beneficiary Gender:

Prescriber Information

- 6. Prescribing Provider NPI #: _____
- 7. Requester Contact Information Name: _____ Phone #: _____ Ext. ___

Drug Information

8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:
11. Length of Therapy (in days):	: Initial Request: 🗌 up to 30 Days 🗌 60 Days 🗌 90 Days 🗌 120 Days 🗌 180 Days	
	Continuation Request: \Box up to 30 Days \Box 60	Days 🗌 90 Days 🗌 120 Days 🗌 180 Days 🗌 365 Days

Clinical Information

- 1. Does the member have a diagnosis of moderate to severe Tardive Dyskinesia? 🗆 Yes 🗆 No
- 2. Is the member age 18 or older?
 Yes
 No
- 3. Has the provider completed baseline evaluations of the condition using either Abnormal Involuntary Movement Scale (AIMS) or Extrapyramidal Symptom Rating Scale (ESRI) along with this request?
 Yes
 No 3b. Please include AIMS score: ______ or ESRI score: _____
- 4. Has the member had a previous trial of an alternative method to manage the condition? \Box Yes \Box No
- 5. Is the member receiving dual therapy with other vesicular monoamine transporter 2 (VMAT2) inhibitors? □ Yes □ No
- 6. Is the member concurrently using a MAOI (Monoamine Oxidase Inhibitor) or reserpine?

For Continuation of Therapy, answer questions 1-6 and attach documentation that indicates the beneficiary has had an improvement in their symptoms from baseline.

Signature	of Prescriber:

_____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.